Refractory Langerhans cell histiocytosis Recruiting Phase 2 Trials for X-396 (DB13104)

Indication	Status	Phase
DBCOND0022006 (Refractory Langerhans cell histiocytosis)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03155620	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Screening	Ensartinib (DB14860) Erdafitinib (DB12147) Hydrogen (DB15127) LY-3023414 (DB12167) Larotrectinib (DB14723) Menthol (DB14123) Olaparib (DB09074) Palbociclib (DB09073) Selpercatinib (DB15685) Selumetinib (DB11689) Sulfate ion (DB14546) Tazemetostat (DB12887) Tipifarnib (DB04960) Ulixertinib (DB13930) Vemurafenib (DB08881) X-396 (DB13104)
NCT03213652	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)	Treatment	Ensartinib (DB14860) X-396 (DB13104)